Teriparatide
FDA ApprovedAlso known as: Forteo, PTH 1-34, Parathyroid Hormone Fragment
Bone & MetabolicLast reviewed: April 28, 2026
A recombinant fragment of parathyroid hormone (amino acids 1-34) FDA-approved for osteoporosis. The first anabolic (bone-building) agent approved for osteoporosis, as opposed to anti-resorptive drugs that only slow bone loss.
Mechanism of Action
Intermittent exposure to PTH(1-34) paradoxically stimulates osteoblast activity more than osteoclast activity, resulting in net bone formation. This is opposite to the bone-resorbing effect of continuously elevated PTH in hyperparathyroidism.
Common Uses
- Severe osteoporosis
- Fracture risk reduction
- Glucocorticoid-induced osteoporosis
- Bone healing acceleration
Known Risks
- Osteosarcoma risk (boxed warning — based on rat studies at high doses)
- Hypercalcemia
- Orthostatic hypotension
- Leg cramps
- Nausea
- Limited to 2 years of use
Regulatory Status
FDA-approved as Forteo (2002) for osteoporosis in postmenopausal women and men at high fracture risk. Limited to 2 years of treatment due to theoretical osteosarcoma risk. Biosimilar (Tymlos/abaloparatide is a related but distinct peptide).
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
20 mcg
Frequency
Once daily
Cycle Length
Up to 24 months (FDA limit)
Self-administered via pen injector in the thigh or abdomen. Must be refrigerated. Follow with anti-resorptive therapy after completing course to maintain bone gains.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.